Certuity’s ARS Pharmaceuticals SPRY Stock Holding History

Certuity’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,000	Closed	-$175K	–	571
2025 Q2	$175K	Buy	+10,000	New	+$144K	0.02%	406

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Certuity's SPRY Position: Q3 2025 in Review

Certuity sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 10,000 shares — an estimated $175K sold.

Certuity first reported a position in SPRY in Q2 2025 and held it in 1 quarter. The position peaked at $175K in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

Certuity reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Certuity sold 10,000 ARS Pharmaceuticals shares in Q3 2025, an estimated $175K.
Certuity first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Certuity's ARS Pharmaceuticals position peaked at $175K in Q2 2025.
188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Certuity's 13F filing for Q3 2025, filed 13 Nov 2025.